IGMS
NASDAQIGM Biosciences Inc.
Price$1.27-0.02 (-1.54%)
2025-06-092025-08-13
Latest news
25 items- SECSEC Form 15-12G filed by IGM Biosciences Inc.15-12G - IGM Biosciences, Inc. (0001496323) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by IGM Biosciences Inc.SCHEDULE 13D/A - IGM Biosciences, Inc. (0001496323) (Subject)
- INSIDERSEC Form 4 filed by Former 10% owner and director Baker Bros. Advisors Lp4 - IGM Biosciences, Inc. (0001496323) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by IGM Biosciences Inc.SCHEDULE 13D/A - IGM Biosciences, Inc. (0001496323) (Subject)
- INSIDERDirector Redmile Group, Llc returned 2,964,843 shares to the company (SEC Form 4)4 - IGM Biosciences, Inc. (0001496323) (Issuer)
- SECSEC Form EFFECT filed by IGM Biosciences Inc.EFFECT - IGM Biosciences, Inc. (0001496323) (Filer)
- SECSEC Form EFFECT filed by IGM Biosciences Inc.EFFECT - IGM Biosciences, Inc. (0001496323) (Filer)
- SECSEC Form EFFECT filed by IGM Biosciences Inc.EFFECT - IGM Biosciences, Inc. (0001496323) (Filer)
- SECSEC Form EFFECT filed by IGM Biosciences Inc.EFFECT - IGM Biosciences, Inc. (0001496323) (Filer)
- SECSEC Form EFFECT filed by IGM Biosciences Inc.EFFECT - IGM Biosciences, Inc. (0001496323) (Filer)
- INSIDERDirector Hambleton Julie returned 2,000 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - IGM Biosciences, Inc. (0001496323) (Issuer)
- INSIDERDirector Lee Michael Stewart returned 12,712 shares to the company (SEC Form 4)4 - IGM Biosciences, Inc. (0001496323) (Issuer)
- INSIDERLarge owner Topsoe Holding A/S returned 10,400,564 shares to the company (SEC Form 4)4 - IGM Biosciences, Inc. (0001496323) (Issuer)
- INSIDERDirector Topsoe Christina Teng returned 10,464,599 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - IGM Biosciences, Inc. (0001496323) (Issuer)
- INSIDERDirector Topsoe Jakob Haldor returned 10,492,276 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - IGM Biosciences, Inc. (0001496323) (Issuer)
- INSIDERDirector Thompson Elizabeth H.Z. returned 7,196 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - IGM Biosciences, Inc. (0001496323) (Issuer)
- INSIDERDirector Strohl William returned 125,000 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - IGM Biosciences, Inc. (0001496323) (Issuer)
- INSIDERChief Executive Officer Harler Mary Beth returned 323,680 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - IGM Biosciences, Inc. (0001496323) (Issuer)
- INSIDERDirector Behrens M Kathleen returned 412,535 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - IGM Biosciences, Inc. (0001496323) (Issuer)
- SECSEC Form S-8 POS filed by IGM Biosciences Inc.S-8 POS - IGM Biosciences, Inc. (0001496323) (Filer)
- SECSEC Form S-8 POS filed by IGM Biosciences Inc.S-8 POS - IGM Biosciences, Inc. (0001496323) (Filer)
- SECSEC Form S-8 POS filed by IGM Biosciences Inc.S-8 POS - IGM Biosciences, Inc. (0001496323) (Filer)
- SECSEC Form S-8 POS filed by IGM Biosciences Inc.S-8 POS - IGM Biosciences, Inc. (0001496323) (Filer)
- SECSEC Form S-8 POS filed by IGM Biosciences Inc.S-8 POS - IGM Biosciences, Inc. (0001496323) (Filer)
- SECSEC Form S-8 POS filed by IGM Biosciences Inc.S-8 POS - IGM Biosciences, Inc. (0001496323) (Filer)
IGMS FAQ
7 questionsWhat does IGM Biosciences Inc. do?
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of multiple diseases. Its lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). The company is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers and NHL; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of...Where does IGMS stock trade?
IGM Biosciences Inc. (IGMS) is listed on NASDAQ.What sector and industry is IGMS in?
IGM Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did IGM Biosciences Inc. go public?
IGM Biosciences Inc. (IGMS) completed its IPO in 2019.What are analysts saying about IGMS?
IGM Biosciences Inc. has had 8 recent analyst actions on file. The most recent action was from BMO Capital Markets: Market Perform with a $200.00 price target on 2025-01-10.What companies are similar to IGMS?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare IGMS side-by-side with any of them on Quantisnow.How can I track IGMS on Quantisnow?
Quantisnow aggregates IGM Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IGMS to receive live email and push alerts on every new disclosure.